Gautam Valecha
Hematology & Oncology · Albuquerque, NMNPI 1235579632
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 124 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by AstraZeneca at 24.6% of the total.
Across 124 payments — averaging $23.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$705
- Novartis$252
- Merck$211
- Pfizer$183
- Takeda Pharmaceuticals U.S.A., Inc.$173
- E.r. Squibb & Sons, L.L.C.$164
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,855100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 30 | $705 |
| Novartis | 10 | $252 |
| Merck | 9 | $211 |
| Pfizer | 8 | $183 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $173 |
| E.r. Squibb & Sons, L.L.C. | 8 | $164 |
| Tempus AI, Inc | 8 | $164 |
| Daiichi Sankyo Inc. | 6 | $157 |
| Bristol Myers Squibb | 5 | $99 |
| Regeneron Healthcare Solutions, Inc. | 1 | $98 |
| Array Biopharma Inc | 4 | $85 |
| Bayer | 3 | $71 |
| Johnson & Johnson | 3 | $58 |
| Incyte Corporation | 3 | $52 |
| Myriad Genetic Laboratories, Inc. | 2 | $49 |
| Genentech USA, Inc. | 2 | $45 |
| Servier Pharmaceuticals LLC | 2 | $42 |
| Sanofi | 1 | $35 |
| Seagen Inc. | 2 | $34 |
| Astellas Pharma US Inc | 1 | $27 |
| Jazz Pharmaceuticals Inc. | 1 | $27 |
| Kedrion Biopharma, Inc. | 1 | $26 |
| Lilly USA, LLC | 1 | $23 |
| Deciphera Pharmaceuticals Inc. | 1 | $21 |
| Fresenius Kabi USA, LLC | 1 | $21 |
| Sobi, Inc | 1 | $20 |
| Pharmaand GmbH | 1 | $13 |
| Karyopharm Therapeutics Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$125
How this compares
$2,867 in reported general payments places this provider in the 55th percentile of 54 hematology & oncology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 12 | $31,864 |
| Anastrozole | 31 | $700 |
| Potassium Chloride | 17 | $350 |
| Prochlorperazine Maleate | 25 | $270 |
| Ondansetron Hcl | 25 | $134 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Albuquerque
- Ursa Brown GlabermanAlbuquerque$219K
- Neda Hashemi SadraeiAlbuquerque$96K
- Muhammad TarakjiAlbuquerque$34K
- Yara AbdouAlbuquerque$25K
- George AtwehAlbuquerque$24K
- Scott HerbertAlbuquerque$14K
- Jose AvitiaAlbuquerque$11K
- Zoneddy DayaoAlbuquerque$10K
- Toufic TannousAlbuquerque$10K
- Amy TarnowerAlbuquerque$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.